<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790448</url>
  </required_header>
  <id_info>
    <org_study_id>VIC-BRAFMT-mCRC</org_study_id>
    <nct_id>NCT04790448</nct_id>
  </id_info>
  <brief_title>Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase Ia/II, Single Arm Trial on the Efficacy of Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicenter, single arm clinical trial was designed to evaluate the&#xD;
      efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the&#xD;
      treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      To evaluate the Overall Response Rate (ORR) of v-raf murine sarcoma viral oncogene homolog B&#xD;
      (BRAF) V600E mutant metastatic colorectal cancer patients treated with Vemurafenib in&#xD;
      combination with Irinotecan and Cetuximab (VIC regimen).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      To evaluate the Progression Free Survival (PFS), Overall Survival (OS), safety and toxicity&#xD;
      of VIC regimen in the treatment of BRAF V600E mutant colon cancer.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      Mechanism of primary and secondary resistance to VIC regimen in the treatment of BRAF V600E&#xD;
      mutant colon cancer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive Cetuximab and Irinotecan intravenously on day 1 and Vemurafenib orally (PO)&#xD;
      twice daily (BID) on days 1 to 14. Courses are repeated every 2 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate from the date of first drug administration until the date of first documented progression or date of death, whichever came first.</measure>
    <time_frame>up to 17 months</time_frame>
    <description>The proportion of patients who achieved a complete or partial response as their best overall response based on RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival from the date of first drug administration until the date of first documented progression or date of death, whichever came first.</measure>
    <time_frame>up to 17 months</time_frame>
    <description>The length of time during and after the treatment of the disease, that a patient lives with the disease without its aggravation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from the date of first drug administration until the date of death from any cause.</measure>
    <time_frame>up to 17 months</time_frame>
    <description>The length of time from the start of treatment that patients diagnosed are still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events and severity according to NCI CTCAE v5.0</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Summary of the Adverse events experienced during treatment related to the drug used in this study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>VIC regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive VIC regimen every 2 weeks:&#xD;
Cetuximab 500mg/m2 IV on Day 1; Irinotecan 180mg/m2 IV on Day 1 (If patient carries UGT*28 7/7 or UGT*6 A/A or UGT*28 6/7 and UGT*6 A/G variants, use Irinotecan IV 150mg/m2 instead); Vemurafenib PO BID on Days 1 to 14 (Dosage: 480mg; 720mg; 960mg, determined by the maximum tolerated dose (MTD) in Phase Ia trial).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Route of administration: Intravenous</description>
    <arm_group_label>VIC regimen</arm_group_label>
    <other_name>C225</other_name>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Route of administration: Intravenous</description>
    <arm_group_label>VIC regimen</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Route of administration: Oral</description>
    <arm_group_label>VIC regimen</arm_group_label>
    <other_name>Zelboraf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of metastatic colorectal cancer&#xD;
&#xD;
          -  Histopathological or ctDNA analysis positive for BRAF V600E mutant&#xD;
&#xD;
          -  Patients must have had at least undergone one first line treatment with FOLFOX or&#xD;
             FOLFIRI or FOLFOXIRI±Bevacizumab before disease progression.&#xD;
&#xD;
          -  Measurable and assessable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Adequate hematologic function (Platelet&gt;90×109/L; White blood cells&gt;3.0×109/L;&#xD;
             Neutrophils&gt;1.5×109/L; Hb&gt;10.0g/100ml)&#xD;
&#xD;
          -  Serum bilirubin ≤1.5 times the upper limit of normal (ULN), transaminase ≤5 times ULN&#xD;
&#xD;
          -  No ascites, normal coagulation function, albumin ≥35g/L&#xD;
&#xD;
          -  Child-Pugh class A&#xD;
&#xD;
          -  Serum creatinine is less than the upper limit of normal (ULN), or calculated&#xD;
             creatinine clearance rate&gt; 50ml/min (using Cockcroft-Gault equation)&#xD;
&#xD;
          -  ECOG performance status of grade 0-2&#xD;
&#xD;
          -  Life expectancy&gt; 3 months&#xD;
&#xD;
          -  Patients must provide a signed Informed Consent Form&#xD;
&#xD;
          -  Patients must have good compliance till the end of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with KRAS and NRAS mutations&#xD;
&#xD;
          -  Previously received anti-EGFR monoclonal antibodies or EGFR inhibitors, BRAF&#xD;
             inhibitors (with the exception of regorafenib)&#xD;
&#xD;
          -  Patients with known contraindications to receiving cetuximab or irinotecan at the&#xD;
             planned dose&#xD;
&#xD;
          -  Patients with retinal vein occlusion or have current risk factors for retinal vein&#xD;
             occlusion (for example, uncontrolled glaucoma or ocular hypertension)&#xD;
&#xD;
          -  History of acute or chronic pancreatitis&#xD;
&#xD;
          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical&#xD;
             intervention (immunomodulatory or immunosuppressive drugs or surgery) within 12 months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Gastrointestinal diseases that may greatly affect the absorption of Vimurafenib (for&#xD;
             example, ulcer disease, uncontrolled vomiting, malabsorption syndrome, small bowel&#xD;
             resection and reduced intestinal absorption)&#xD;
&#xD;
          -  Neuromuscular diseases associated with elevated CK (eg, inflammatory myopathy,&#xD;
             muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)&#xD;
&#xD;
          -  Patients with any residual CTCAE ≥ Grade 2 toxicity from previous anti-tumor therapy&#xD;
             (excluding hair loss or neuropathy of Grade 2 and above)&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Active hepatitis B or C infection&#xD;
&#xD;
          -  History of Gilbert syndrome&#xD;
&#xD;
          -  Interstitial pneumonia or widespread symptomatic interstitial pulmonary fibrosis&#xD;
&#xD;
          -  Serious uncontrollable systemic complications such as infection or diabetes&#xD;
&#xD;
          -  Clinically serious cardiovascular diseases such as cerebrovascular accident (within 6&#xD;
             months prior to enrollment), myocardial infarction (within 6 months prior to&#xD;
             enrollment), hypertension that cannot be controlled after proper medical treatment,&#xD;
             unstable angina pectoris, congestion Heart failure (NYHA 2-4), arrhythmia requiring&#xD;
             medication&#xD;
&#xD;
          -  History of or showing signs of a central nervous system disease (such as primary brain&#xD;
             tumors, epilepsy that cannot be controlled by standard treatment, any brain metastases&#xD;
             or history of stroke)&#xD;
&#xD;
          -  Patients must not suffer from other uncontrolled concurrent diseases, including but&#xD;
             not limited to hypertensive crisis or hypertensive encephalopathy, active bleeding,&#xD;
             uncontrolled infections/diseases, uncontrolled non-malignant medical diseases or use&#xD;
             research therapies that could worsen non-malignant medical diseases or mental&#xD;
             illnesses/social conditions&#xD;
&#xD;
          -  No history of other malignant tumors in the past 5 years (excluding skin basal cell&#xD;
             carcinoma and/or cervical carcinoma in situ and/or thyroid cancer after radical&#xD;
             resection)&#xD;
&#xD;
          -  Patients allergic to any drugs in the study&#xD;
&#xD;
          -  Patients must not be pregnant or breastfeeding&#xD;
&#xD;
          -  Women of reproductive potential (&lt;2 years after the last menstruation) who have not&#xD;
             used or refused to use effective non- hormonal contraceptive methods (intrauterine&#xD;
             contraceptive ring, barrier contraception combined with spermicidal gel or&#xD;
             sterilization) or Men wanting to keep their reproductive potential.&#xD;
&#xD;
          -  Patients unable or unwilling to comply with the protocol of this clinical trial&#xD;
&#xD;
          -  Existence of any other diseases, dysfunction caused by metastatic lesions, or&#xD;
             suspicious diseases found during physical examination, which may indicate&#xD;
             contraindications to the use of the drugs in this study or could bring about high risk&#xD;
             of treatment-related complications to the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuhong Li</last_name>
    <phone>020-87342487</phone>
    <email>liyh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhong Li, MD</last_name>
      <phone>+86(20)87343135</phone>
      <email>liyh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

